(4-溴苄基)磷酸 | 40962-34-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-溴苄基)磷酸
• 英文名称: [(4-bromophenyl)methyl]phosphonic acid
• 英文别名: 4-bromobenzylphosphonic acid；p-Brombenzylphosphonsaeure；(4-bromophenyl)methylphosphonic Acid
• CAS: 40962-34-3
• 化学式: C₇H₈BrO₃P
• 分子量: 251.016
• InChiKey: AJSDTRXBGITXHM-UHFFFAOYSA-N

物化性质

• 熔点：
  189-193°C
• 沸点：
  438.6±47.0 °C(Predicted)
• 密度：
  1.779±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  (4-溴苄基)磷酸 在 氯化亚砜 作用下， 反应 20.0h， 生成 (4-Bromobenzyl)phosphonsaeure-dichloride
  参考文献：
  名称：

  Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the Acanthocheilonema viteae Product ES-62 Prevents Development of Collagen-Induced Arthritis

  摘要：

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,

  DOI：

  10.1021/jm401251p
• 作为产物：
  描述：

  4-溴苄基亚磷酸二乙酯 在 三甲基溴硅烷 作用下， 以 二氯甲烷 为溶剂， 生成 (4-溴苄基)磷酸
  参考文献：
  名称：

  用于水相容性 SN2 18F-氟化小分子放射性示踪剂的“AquaF”构建模块

  摘要：

  尽管广泛使用亲水结构单元来掺入18 F 并改善示踪剂药代动力学，但在水中实现有效的离去基团介导的亲核18 F-氟化（不包括18 F/ 19 F-交换）仍然是一个艰巨的挑战。在这里，我们提出了一种水相容的 S N 2 离去基团介导的18 F-氟化方法，该方法采用预共轭的“AquaF”（膦酰胺氟化物）构建块。在 19 个紧凑的四配位五价 P(V)–F 候选物中，“AquaF”结构单元表现出优异的水溶性、在水中足够的18 F-氟化能力以及优异的体内代谢特性。从候选离去基团池中鉴定出两个硝基吡啶醇离去基团，可进一步增强前体水溶性，能够在水中以 10 –2 M –1 s –1级反应速率常数进行18 F-氟化（超过18 F/ 19 F-交换）在室温下。随着放能协同 S N 2 18 F-氟化机制的确认，这种18 F-氟化方法实现了~90%的放射化学转化率，并在盐水中达到了 175 ± 40 GBq/μmol（使用

  DOI：

  10.1021/jacs.4c05854

文献信息

• [EN] COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS<br/>[FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013027001A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6, X1, X2, X3, X4, A1 and L1, are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（1）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、m、n、p、q、Q1、Q2、Q3、Q4、Q5、Q6、X1、X2、X3、X4、A1和L1如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• Substrate-Based Fragment Identification for the Development of Selective, Nonpeptidic Inhibitors of Striatal-Enriched Protein Tyrosine Phosphatase
  作者：Tyler D. Baguley、Hai-Chao Xu、Manavi Chatterjee、Angus C. Nairn、Paul J. Lombroso、Jonathan A. Ellman

  DOI：10.1021/jm401037h

  日期：2013.10.10

  Alzheimer’s disease. Herein, a substrate-based approach for the discovery and optimization of fragments called substrate activity screening (SAS) has been applied to the development of low molecular weight (<450 Da) and nonpeptidic, single-digit micromolar mechanism-based STEP inhibitors with greater than 20-fold selectivity across multiple tyrosine and dual specificity phosphatases. Significant levels of

  在许多神经精神疾病如阿尔茨海默病中观察到高水平的纹状体富集蛋白酪氨酸磷酸酶 (STEP) 活性。STEP 的过度表达导致许多关键神经元信号分子的去磷酸化和失活，包括离子型谷氨酸受体。此外，降低 AD 小鼠模型中 STEP 水平的基因显着逆转了认知缺陷并降低了谷氨酸受体内化。这些结果支持 STEP 作为治疗阿尔茨海默病药物发现的潜在靶点。在此，一种用于发现和优化称为底物活性筛选 (SAS) 的基于底物的方法已应用于低分子量 (<450 Da) 和非肽类的开发，基于单位数微摩尔机制的 STEP 抑制剂，对多种酪氨酸和双特异性磷酸酶的选择性超过 20 倍。还观察到大鼠皮层神经元中显着水平的 STEP 抑制。
• Selective Esterification of Phosphonic Acids
  作者：Damian Trzepizur、Anna Brodzka、Dominik Koszelewski、Ryszard Ostaszewski

  DOI：10.3390/molecules26185637

  日期：——

  proposed methodology was verified on aromatic as well as aliphatic phosphonic acids. The designed method can be successfully applied for small- and large-scale experiments without significant loss of selectivity or reaction yield. Several devoted experiments were performed to give insight into the reaction mechanism. At 30 °C, monoesters are formed via an intermediate (1,1-diethoxyethyl ester of phosphonic

  在这里，我们报告了膦酸单酯化和二酯化的直接和选择性合成程序。研究了一系列烷氧基供体，发现原乙酸三乙酯是进行转化的最佳试剂和溶剂。发现了对反应过程的重要温度影响。取决于反应温度，以合适的产率专门获得膦酸的单乙酯或二乙酯。所提出的方法的底物范围在芳香族和脂肪族膦酸上得到验证。所设计的方法可成功应用于小规模和大规模实验，而不会显着降低选择性或反应收率。进行了几次专门的实验以深入了解反应机理。在 30 °C 时，单酯通过中间体（膦酸的 1,1-二乙氧基乙酯）形成。在更高的温度下，类似的中间体形式产生二酯或稳定且可检测的焦膦酸盐，它们也被消耗以产生二酯。31 P NMR 光谱用于确定焦膦酸酯的结构并监测反应过程。不需要额外的试剂、良好的可及性和直接的纯化是所开发协议的重要方面。
• AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME
  申请人：Idemitsu Kosan Co., Ltd.

  公开号：EP2634170A1

  公开（公告）日：2013-09-04

  A compound is shown by the following formula (1). wherein I, m, and n are independently an integer from 1 to 3, Ar1 to Ar4 are independently a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms, or a substituted or unsubstituted heteroaryl group having 5 to 30 ring atoms, Ar5, Ar6, and Ar7 are independently a substituted or unsubstituted arylene group having 6 to 30 ring carbon atoms, or a substituted or unsubstituted heteroarylene group having 5 to 30 ring atoms, and p is an integer from 0 to 2, and Ar6 and N are bonded via a single bond when p is 0, provided that at least one of Ar1 to Ar4 is substituted with a substituted silyl group, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, or a substituted or unsubstituted cycloalkyl group having 3 to 10 carbon atoms, and at least one of Ar1 to Ar4 is substituted with a cyano group.

  公式（1）显示了一个化合物，其中I、m和n分别是从1到3的整数，Ar1到Ar4分别是具有6到30个环碳原子的取代或未取代芳基基团，或者是具有5到30个环原子的取代或未取代杂芳基基团，Ar5、Ar6和Ar7分别是具有6到30个环碳原子的取代或未取代芳撑基团，或者是具有5到30个环原子的取代或未取代杂芳撑基团，p是从0到2的整数，当p为0时，Ar6和N通过单键结合，前提是Ar1到Ar4中至少有一个被取代为取代硅基基团、具有1到20个碳原子的取代或未取代烷基基团，或者具有3到10个碳原子的取代或未取代环烷基基团，而Ar1到Ar4中至少有一个被取代为氰基。
• NOVEL SILICON-TYPE COMPOUND AND AN ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE USING THE SAME
  申请人：MOON Hyoung-don

  公开号：US20090045734A1

  公开（公告）日：2009-02-19

  The present invention relates to a silicon compound and an organic electroluminescent device using the same, and more particularly, to a silicon compound which has good blue light emission and enables an organic electroluminescent device to have a low voltage, high brightness and long lifetime, and an organic luminescent display device using the same.

  本发明涉及一种硅化合物和使用该硅化合物的有机电致发光装置，更具体地涉及一种具有良好的蓝光发射并使有机电致发光装置具有低电压、高亮度和长寿命的硅化合物，以及使用该硅化合物的有机发光显示装置。